ReviewInternational journal of nanomedicine2026
Nanotechnology for the Treatment of Radiation Dermatitis: Advances and Translational Perspectives.
Review in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Radiation dermatitis is the most common complication of radiotherapy, but conventional treatments only alleviate some symptoms, with limited efficacy and safety, thus necessitating the exploration of novel therapeutic strategies. This review synthesizes current understanding of radiation dermatitis pathogenesis, and highlights recent advances enabled by nanomaterial-based strategies. We categorize nanomaterials according to their mechanisms of action and pathological stage-specific application in radiation dermatitis. Fullerene alcohol, a representative direct antioxidant material-has demonstrated preliminary clinical efficacy; immune microenvironment-modulating materials exert therapeutic effects on chronic inflammation and fibrosis via synergistic, multi-pathway regulation; and composite biomaterials enable coordinated, multi-targeted repair. We further identify key translational barriers impeding clinical translation: biological safety, scalable manufacturing, regulatory uncertainty, and tumor safety risks. Future efforts should prioritize collaborative safety assessment, scalable manufacturing, and stage-tailored clinical trials to accelerate the clinical adoption of nanomaterials.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.